Items Tagged ‘Florida News Release’
October 21st, 2014 · Leave a Comment
By Paul Scotti
Years After Treatment for HER2-Positive Early Stage Breast Cancer Trastuzumab Shows Life-Altering Benefit
JACKSONVILLE, Fla. — After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.
They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone.
These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. Read the rest of this entry »
September 29th, 2014 · Leave a Comment
By Paul Scotti
JACKSONVILLE, Fla., Sept. 29, 2014 — Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.
September 19th, 2014 · Leave a Comment
By Kevin Punsky
JACKSONVILLE, Fla. — Researchers at Jacksonville’s campus of Mayo Clinic have discovered a defect in a key cell-signaling pathway they say contributes to both overproduction of toxic protein in the brains of Alzheimer’s disease patients as well as loss of communication between neurons — both significant contributors to this type of dementia.
Their study, in the online issue of Neuron, offers the potential that targeting this specific defect with drugs “may rejuvenate or rescue this pathway,” says the study’s lead investigator, Guojun Bu, Ph.D., a neuroscientist at Mayo Clinic, Jacksonville, Fla.
“This defect is likely not the sole contributor to development of Alzheimer’s disease, but our findings suggest it is very important, and could be therapeutically targeted to possibly prevent Alzheimer’s or treat early disease,” he says.
September 12th, 2014 · Leave a Comment
By Paul Scotti
JACKSONVILLE, Fla., Sept. 12, 2014 — The liver transplant team at Mayo Clinic in Florida has found, based on 12 years of experience, that more than half of patients receiving a new liver can be “fast-tracked” to return to a surgical ward room following their transplant, bypassing a one- or two-day stay in the Intensive Care Unit (ICU).
In the September issue of the American Journal of Transplantation, the physicians and researchers have turned their knowledge of who can be safely fast-tracked into a scoring system that other transplant centers can also use — thus sparing patients potentially overly aggressive treatment and saving substantial health care dollars.
September 12th, 2014 · Leave a Comment
By Kevin Punsky
JACKSONVILLE, Fla. — Physicians envision a future in which genomic data from patients is heavily used to manage care — but experts have questioned the accuracy and reliability of these analyses. Now, a study by 150 researchers in 12 countries finds real strength and agreement across RNA genomic sequencing techniques and laboratories — as well as ways to improve what little variability exists to set a new high standard.
The results of the study were published in Nature Biotechnology in three separate research articles.
These results should provide assurance to patients, clinicians and the research community that genomic sequencing is accurate, says E. Aubrey Thompson, Ph.D., a professor of cancer biology at Mayo Clinic in Florida, one of three institutions that led the study. Dr. Thompson is a study co-author and member of the project leadership. Read the rest of this entry »
September 2nd, 2014 · Leave a Comment
By Paul Scotti
JACKSONVILLE, Fla., Sept. 2, 2014 – Mayo Clinic and the University of North Florida are honoring National Breast Cancer Awareness Month in October by hosting the tenth annual “Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship” concert on Friday, Oct. 10 at 7:30 p.m. in Lazzara Performance Hall, UNF Fine Arts Building on the university’s campus in Jacksonville. The Upbeat Pink concert is free and open to the public.
The theme for this year’s program, “Dancing with the Survivors,” showcases a variety of dance music performed by the UNF Wind Symphony, conducted by Gordon Brock, D.M.A., and features special guest artist and multi-instrumentalist, Bill Prince, D.M.A.
Tags: Breast Cancer, Breast Clinic, Donna Foundation, Florida News Release, Gordon Brock Bill Prince, Laura Vallow, M.D., Mayo Clinic, News Release, UNF Wind Symphony, University of North Florida, Upbeat Pink, 262 with Donna
August 18th, 2014 · Leave a Comment
JACKSONVILLE, Fla. — Mayo Clinic’s stroke center in Jacksonville is the first center in Florida to receive national Comprehensive Stroke Center certification, joining an elite group of centers throughout the United States that are focused on providing advanced and complex stroke care.
Centers that achieve this distinction — awarded by The Joint Commission working with the American Heart Association and the American Stroke Association — are recognized as leaders that help set the national agenda in highly specialized stroke care. The Joint Commission is the nation's oldest and largest standards-setting and accrediting body in health care.
Tags: cerebrovascular, Comprehensive Stroke Center, Dr. David Miller, Florida News Release, interventional radiology, Mayo Clinic, Mayo Clinic in Florida, neurology, neurosurgery, News Release, stroke, telestroke, The Joint Commission, MayoClinicFL
August 14th, 2014 · Leave a Comment
By Kevin Punsky
Potential biomarker discovered to monitor disease progression, therapy
JACKSONVILLE, Fla. — A team of researchers at Mayo Clinic and The Scripps Research Institute in Florida have developed a new therapeutic strategy to combat the most common genetic risk factor for the neurodegenerative disorders amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and frontotemporal dementia (FTD). In the Aug. 14 issue of Neuron, they also report discovery of a potential biomarker to track disease progression and the efficacy of therapies.
The scientists developed a small-molecule drug compound to prevent abnormal cellular processes caused by a mutation in the C9ORF72 gene. The findings come on the heels of previous discoveries by Mayo investigators that the C9ORF72 mutation produces an unusual repetitive genetic sequence that causes the buildup of abnormal RNA in brain cells and spinal cord.
While toxic protein clumps have long been implicated in neurodegeneration, this new strategy takes aim at abnormal RNA, which forms before toxic proteins in C9ORF72-related disorders (c9FTD/ALS). “Our study shows that toxic RNA produced in people with the c9FTD/ALS mutation is indeed a viable drug target,” says the study’s co-senior investigator, Leonard Petrucelli, Ph.D., a molecular neuroscientist at Mayo Clinic in Florida.
The compound, which was tested in cell culture models of c9FTD/ALS, bound to and blocked RNA’s ability to interact with other key proteins, thereby preventing the formation of toxic RNA clumps and “c9RAN proteins” that results from a process called repeat-associated non-ATG (RAN) translation.
The researchers also discovered that c9RAN proteins produced by the abnormal RNA can be measured in the spinal fluid of ALS patients. They are now evaluating whether these proteins are also present in spinal fluid of patients diagnosed with FTD. Although ALS primarily affects motor neurons leading to impaired mobility, speech, swallowing, and respiratory function and FTD affects brain regions that support higher cognitive function, some patients have symptoms of both disorders.
“Development of a readily accessible biomarker for the c9FTD/ALS mutation may aid not only diagnosis of these disorders and allow for tracking disease course in patients, but it could provide a more direct way to evaluate the response to experimental treatments,” says co-author Kevin Boylan, M.D., medical director of the Mayo Jacksonville ALS Center, the only ALS Certified Center of Excellence in Florida. Read the rest of this entry »
August 8th, 2014 · Leave a Comment
Board Also Recognizes Four Recipients of Mayo Clinic Named Professorships
JACKSONVILLE, Fla., and ROCHESTER, Minn. — The Mayo Clinic Board of Trustees has named Gianrico Farrugia, M.D., Mayo Clinic vice president and chief executive officer of Mayo Clinic's campus in Jacksonville, Florida. Dr. Farrugia succeeds William Rupp, M.D., who will retire from Mayo Clinic at the end of 2014. The announcement was made today at the Mayo Clinic Board of Trustees quarterly meeting where the board also recognized four recipients of Mayo Clinic named professorships.
Soundbites of Dr. Noseworthy are available in the downloads box.
“Dr. Farrugia brings a wealth of experience to his new role,” says John Noseworthy, M.D., Mayo Clinic president and chief executive officer. “He is a physician-leader who brings to this important role a deep commitment to Mayo’s values, mission and strategic vision, along with a passion to lead and equip teams to reach more patients and strengthen Mayo Clinic’s position as a global health care leader. He has a strong commitment to continuing Dr. Rupp’s legacy of involvement and leadership in the Jacksonville community.”
Dr. Farrugia has been with Mayo Clinic for more than 26 years as a physician in the Division of Gastroenterology and Hepatology and Division of Physiology and Biomedical Engineering at Mayo Clinic’s campus in Rochester, Minnesota. He is also a professor of medicine as well as physiology and biomedical engineering. Dr. Farrugia has served in numerous leadership roles at Mayo Clinic with multisite responsibilities, both in his specialty and at the organizational leadership level. He currently serves as director of the Mayo Clinic Center for Individualized Medicine and director of Mayo Clinic’s Enteric Neuroscience Program. He previously served as research chair of the Department of Medicine.
In his new role, Dr. Farrugia will work with Bob Brigham, chief administrative officer in Florida, to provide leadership and direction, defining and implementing Mayo Clinic’s operational plan and continuing to expand Mayo Clinic’s leadership and reach in the Southeast and beyond.
Read the rest of this entry »
Tags: Bob Brigham, Dr. Gianrico Farrugia, Dr. John Noseworthy, Dr. William Rupp, Enteric Neuroscience Program, Florida News Release, Mayo Clinic, Mayo Clinic Board of Trustees, Mayo Clinic in Florida, News Release
August 4th, 2014 · Leave a Comment
JACKSONVILLE, Fla. — Mayo Clinic in Jacksonville has been recognized as one of the first facilities in the nation to receive the Blue Distinction Centers+SM designation in the area of transplant care. Awarded through Florida Blue as part of a national program from the Blue Cross and Blue Shield companies, the designation recognizes hospitals shown to deliver high-quality specialty care based on objective, transparent measures for patient safety and health outcomes that were developed with input from the medical community.
Mayo Clinic in Florida is also recognized as a Blue Distinction Center for its quality care and services in the areas of cardiac care, hip and knee replacements and spine surgery. Read the rest of this entry »
Tags: Blue Cross and Blue Shield, Blue Distinction Center, BMT, bone marrow transplant, Dr Thomas Gonwa, Florida Blue, Florida News Release, heart transplant, hip replacement, kidney transplant, Knee Replacement, lung transplant, Mayo Clinic in Florida, spine surgery, liver transplant